All In Biotech

Drug Trial Radar · NCT02949895

Study of BMS-986012 in Subjects With Small Cell Lung Caner

A Phase 1 Study of the Safety and Tolerability of BMS-986012 in Subjects With Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Aug 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

7

Actual

Start

Nov 29, 2016

Primary completion

Aug 29, 2017

Study completion Aug 29, 2017

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Oct 31, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate safety and tolerability of BMS-986012 in patients with small cell lung cancer

Conditions

  • Small Cell Lung Cancer

Interventions

  • BMS-986012Drug

  • CisplatinDrug

  • EtoposideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Up to 2 years
  2. Number of participants with serious adverse events (SAEs )Time frame: Up to 2 years
  3. Number of Discontinuations due to AEsTime frame: Up to 2 years
  4. Number of Deaths due to AEsTime frame: Up to 2 years
  5. Number of participants with laboratory toxicity grade shift from baselineTime frame: Up to 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution

    Takatsuki-shi, Osaka, Japan

  • Local Institution

    Chuo-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.